Wednesday 8:15 – 8:45 Industry theatre 2

Rethinking patient care in UC with a first-in-class advanced oral therapy

This BMS-sponsored symposium will review the current unmet needs in the management of ulcerative colitis and discuss how advanced oral therapies such as ozanimod, a selective S1P receptor modulator, may help to address them. The faculty will review the key data from clinical trials of ozanimod and provide practical insights on managing patients with the drug in clinical practice, before coming together to answer key questions from the audience.


  • Alissa Walsh (Chairperson) John Radcliffe Hospital, Oxford, UK. 
  • Bincy Abraham, Houston Methodist, Weill Cornell, Houston, Texas, USA


08.15-08.20 Welcome and introduction
Alissa Walsh (UK)

08.20-08.40 Expert insights: managing UC with oral S1P receptor modulators
Bincy Abraham (US) / Alissa Walsh (UK)

08.40-08.45 Q&A 

08.45 Summary and close
Alissa Walsh (UK)